KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2026)

Amneal Pharmaceuticals has reported Other financing activities over the past 6 years, most recently at $73.2 million for Q3 2025.

For Q3 2025, Other financing activities changed N/A year-over-year to $73.2 million; the TTM value through Sep 2025 reached $235.6 million, up 45.09%, while the annual FY2023 figure was $162.4 million, 9666.39% up from the prior year.
Other financing activities for Q3 2025 was $73.2 million at Amneal Pharmaceuticals, down from $161.9 million in the prior quarter.
Over five years, Other financing activities peaked at $161.9 million in Q4 2023 and troughed at $41000.0 in Q3 2022.
A 3-year average of $58.9 million and a median of $36.9 million in 2023 define the central range for Other financing activities.
On a YoY basis, Other financing activities climbed as much as 1221.95% in 2023 and fell as far as 1221.95% in 2023.
Year by year, Other financing activities stood at $41000.0 in 2022, then skyrocketed by 394712.2% to $161.9 million in 2023, then tumbled by 54.76% to $73.2 million in 2025.
Business Quant data shows Other financing activities for AMRX at $73.2 million in Q3 2025, $161.9 million in Q4 2023, and $542000.0 in Q3 2023.